CONTINUE TO SITE
OR WAIT 15 SECS
The Ministry of Health, Labour, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD
Japan-headquartered Astellas Pharma Inc. and Yaskawa Electric Corporation have signed a definitive a
SK Chemicals, which developed Korea's first herbal medicine product for osteoarthritis, Joins, has expand
A new ‘nanoball’ vaccine platform developed by experts in Japan will be tested as part of new rese
Taiwan-based Formosa Group Executive Committee member and Chairman Sandy Wang, who leads the group's bio and e
Infinitus (China) Company has secured approval for its Sino-British Joint Laboratory on Health and Ageing proj
Seoul Medical Group (SMG) and Korean American Medical Group (KAMG), the two leading Asian-American-focused med
Thailand's Chulalongkorn University has introduced the Exoskeleton Wheelchair, an innovative ro
Amaran Biotechnology Inc., a subsidiary of OBI Pharma specialising in Contract Development and Manufacturing O
WuXi XDC Cayman Inc., a leading global CRDMO (Contract Research, Development, and Manufacturing Organization)
Mitigating PATENT CLIFF Fallout
Monoclonal antibodies (mAbs) represent a $279.8 billion market, projected to reach $804 billion by 2033, according to a report from Dimension Market Research. With patents for many of these valuable drugs set to expire in the coming years, the industry faces significant challenges. In this story, we examine 11 blockbuster mAbs whose patents will expire between 2025 and 2030. These expirations, affecting some of pharma's biggest players, will have a major impact on the market and their revenue streams.
ISPOR 2025
ISPOR
info@ispor.org https://www.ispor.org/conferences-education/event/2025/05/13/default-calendar/ispor-2025Montreal
Aseptic Conference 2025
ISPE
ask@ispe.org https://ispe.org/conferences/2025-aseptic-conferenceArlington USA
